Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation

(2017) Ying Bai et al.   STROKE

Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction

(2017) Patricia O. Guimarães et al.   JAMA Cardiology

Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data

(2016) Inmaculada Hernandez et al.   American Journal of Cardiovascular Drugs

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation

(2016) Peter A. Noseworthy et al.   CHEST

Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project

(2016) Wen-Hua Li et al.   CLINICAL CARDIOLOGY

The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic

(2016) Faris Al-Khalili et al.   CURRENT MEDICAL RESEARCH AND OPINION

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants

(2016) Steve Deitelzweig et al.   CURRENT MEDICAL RESEARCH AND OPINION

Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials

(2016) Guowei Li et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

(2016) Yi-Hsin Chan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stroke prevention in atrial fibrillation

(2016) Ben Freedman et al.   LANCET

Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care

(2016) Anders Gorst-Rasmussen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

(2016) Allison Keshishian et al.   THROMBOSIS AND HAEMOSTASIS

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation

(2016) David J. Graham et al.   JAMA Internal Medicine

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013

(2014) J. B. Olesen et al.   EUROPACE

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

(2014) Torben Larsen et al.   THROMBOSIS AND HAEMOSTASIS

Comparison of Registered and Published Primary Outcomes in Randomized Clinical Trials of Surgical Interventions

(2013) Gerjon Hannink et al.   ANNALS OF SURGERY

Worldwide Epidemiology of Atrial Fibrillation

(2013) Sumeet S. Chugh et al.   CIRCULATION

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation

(2012) Francesco Dentali et al.   CIRCULATION

Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation

(2012) William L. Baker et al.  

Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation

(2012) Sebastian Schneeweiss et al.  

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Danger Ahead: Watch Out for Indirect Comparisons!⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

(2012) Christopher P. Cannon et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation

(2012) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

(2012) Jack Ansell et al.   THROMBOSIS AND HAEMOSTASIS

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

(2012) L. H. Rasmussen et al.   BMJ-British Medical Journal

GRADE guidelines: 8. Rating the quality of evidence—indirectness

(2011) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE